Company / R&D per Share
Allogene Therapeutics, Inc. R&D per Share History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.71
FY2025
5-year range
$0.71 / $1.53
FY2021-FY2025
Trend
-50.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $1.53 to $0.71 over the past 2 years.
Based on SEC 10-K filings.
0.71 in FY2025 with a 3-year CAGR of -4.9%.
Declined from $1.53 to $0.71 over the past 2 years.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -4.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, r&d per share decreased 50.9% year-over-year.
- Peak r&d per share was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.27 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.71 | -50.9% |
| FY2024 | $1.44 | -6.1% |
| FY2023 | $1.53 | +86.4% |
| FY2022 | $0.82 | -20.0% |
| FY2021 | $1.03 | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026